BG-12 for moderate to severe psoriasis - horizon scanning review

NHSC

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
NHSC. BG-12 for moderate to severe psoriasis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC) 2005: 5

Authors' objectives
This study aims to assess the effectiveness of BG-12 for moderate to severe psoriasis.

Authors' conclusions
BG-12 (dimethyl fumarate) is an orally administered immunomodulator, from a class of products known as fumaric acid esters (FAEs). BG-12 is a second generation FAE product based on Fumaderm (containing mixed dimethyl fumarate and monoethylfumarate salts, and associated with adverse effects) which was licensed in 1994 in Germany for the treatment of psoriasis. There are currently no published trials of clinical effectiveness at this time.

Timeliness warning
Available on request from NHSC.

Final publication URL
http://www.hsric.nihr.ac.uk/search

Indexing Status
Subject indexing assigned by CRD

MeSH
Psoriasis /drug therapy

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
Department of Public Health & Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk

AccessionNumber
32005000243

Date bibliographic record published
13/05/2005
Date abstract record published
13/05/2005